{"disease":{"id":"falciparum-malaria","name":"Falciparum malaria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"atovaquone-and-proguanil","indication_name":"Prophylaxis of P. falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Atovaquone and Proguanil","company_name":"State University of New York - Upstate Medical University","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"atovaquone-and-proguanil","indication_name":"Treatment of acute, uncomplicated P. falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Atovaquone and Proguanil","company_name":"State University of New York - Upstate Medical University","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"artesunate","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artesunate","generic_name":"ARTESUNATE","company_name":"Amivas","drug_phase":"marketed","molecular_target":"","drug_class":"artesunate","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"doxycyclin","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydroxychloroquine-pill","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"hydroxychloroquine-pill","company_name":"Sanofi","drug_phase":"discontinued","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":null,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases."},{"drug_id":"hydroxychloroquine-pill","indication_name":"Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"hydroxychloroquine-pill","company_name":"Sanofi","drug_phase":"discontinued","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":null,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases."},{"drug_id":"sulfafurazole","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantrisin","generic_name":"sulfafurazole","company_name":"Alra","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Sulfonamide Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"artemisinin","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artemef","generic_name":"ARTEMISININ","company_name":"","drug_phase":"phase_3","molecular_target":"Cytochrome P450 1A2","drug_class":"artemisinin","quality_score":31,"revenue":null,"mechanism":"Artemef works by generating reactive oxygen species that rapidly kill malaria parasites."},{"drug_id":"lumefantrine","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coartem","generic_name":"LUMEFANTRINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antimalarial [EPC]","quality_score":65,"revenue":null,"mechanism":"Coartem Tablets, a combination of artemether and lumefantrine, act as an antimalarial agent."},{"drug_id":"halofantrine","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halfan","generic_name":"HALOFANTRINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antimalarial","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"arsuamoon","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arsuamoon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":7,"revenue":null,"mechanism":null},{"drug_id":"mefloquine","indication_name":"Chloroquine Resistant Plasmodium Falciparum Malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lariam","generic_name":"MEFLOQUINE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Antimalarial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mefloquine","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lariam","generic_name":"MEFLOQUINE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Antimalarial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chloroquine","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aralen","generic_name":"CHLOROQUINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Antimalarial","quality_score":65,"revenue":null,"mechanism":"Aralen works by accumulating in the acidic compartments of the malaria parasite, disrupting its metabolism and ultimately leading to its death."},{"drug_id":"chloroquine","indication_name":"Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aralen","generic_name":"CHLOROQUINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Antimalarial","quality_score":65,"revenue":null,"mechanism":"Aralen works by accumulating in the acidic compartments of the malaria parasite, disrupting its metabolism and ultimately leading to its death."},{"drug_id":"quinine","indication_name":"Chloroquine Resistant Plasmodium Falciparum Malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qualaquin","generic_name":"QUININE","company_name":"Sun Pharm Industries","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"Antimalarial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"quinine","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qualaquin","generic_name":"QUININE","company_name":"Sun Pharm Industries","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"Antimalarial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"hydroxychloroquine","indication_name":"Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"artesunate-amodiaquine-as-aq","indication_name":"Treatment of acute, uncomplicated Plasmodium falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"artesunate-amodiaquine (AS-AQ)","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase","drug_class":"Artemisinin derivative + aminoquinoline antimalarial combination","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"proguanil","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Malarone","generic_name":"PROGUANIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":60,"revenue":null,"mechanism":"Malarone works by inhibiting the parasite's ability to synthesize nucleic acids, ultimately preventing its replication and spread within the body."},{"drug_id":"proguanil","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Malarone","generic_name":"PROGUANIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":60,"revenue":null,"mechanism":"Malarone works by inhibiting the parasite's ability to synthesize nucleic acids, ultimately preventing its replication and spread within the body."},{"drug_id":"proguanil","indication_name":"Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Malarone","generic_name":"PROGUANIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":60,"revenue":null,"mechanism":"Malarone works by inhibiting the parasite's ability to synthesize nucleic acids, ultimately preventing its replication and spread within the body."},{"drug_id":"artemether","indication_name":"Chloroquine Resistant Plasmodium Falciparum Malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coartem","generic_name":"ARTEMETHER","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":10,"revenue":null,"mechanism":"Artemether works by rapidly killing malaria parasites in the blood and liver."},{"drug_id":"arterolane","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ARTEROLANE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mefloquine-hydrochloride","indication_name":"Chloroquine Resistant Plasmodium Falciparum Malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lariam","generic_name":"MEFLOQUINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Antimalarial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mefloquine-hydrochloride","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lariam","generic_name":"MEFLOQUINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Antimalarial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"atovaquone","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepron","generic_name":"ATOVAQUONE","company_name":"","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Antimalarial [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepron works by inhibiting the electron transport chain in the mitochondria of Plasmodium parasites, ultimately leading to their death."},{"drug_id":"atovaquone","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepron","generic_name":"ATOVAQUONE","company_name":"","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Antimalarial [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepron works by inhibiting the electron transport chain in the mitochondria of Plasmodium parasites, ultimately leading to their death."},{"drug_id":"atovaquone","indication_name":"Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepron","generic_name":"ATOVAQUONE","company_name":"","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Antimalarial [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepron works by inhibiting the electron transport chain in the mitochondria of Plasmodium parasites, ultimately leading to their death."},{"drug_id":"doxycycline","indication_name":"Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquin","indication_name":"Falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxychloroquin","company_name":"Children's Hospital of Fudan University","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxychloroquin","indication_name":"Plasmodium Falciparum Malaria Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxychloroquin","company_name":"Children's Hospital of Fudan University","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":34,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05052502","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","phase":"NA","overall_status":"UNKNOWN","enrollment_count":49118,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03783299","title":"Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":39968,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04416945","title":"Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic","phase":"NA","overall_status":"UNKNOWN","enrollment_count":31443,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05306067","title":"Plasmodium Falciparum Genomic Intelligence in Mozambique","phase":"","overall_status":"COMPLETED","enrollment_count":21848,"lead_sponsor_name":"Centro de Investigacao em Saude de Manhica","has_results":false},{"nct_id":"NCT06529237","title":"Malaria Molecular Surveillance in Mozambique (Phase 2)","phase":"","overall_status":"RECRUITING","enrollment_count":18750,"lead_sponsor_name":"Centro de Investigacao em Saude de Manhica","has_results":false},{"nct_id":"NCT04839900","title":"Proactive Community Case Management for Malaria in Zambia","phase":"NA","overall_status":"COMPLETED","enrollment_count":10890,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT04864444","title":"Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities","phase":"NA","overall_status":"COMPLETED","enrollment_count":10715,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06068530","title":"Mass Vaccine and Drug Administration, Bangladesh","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT07389057","title":"Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","phase":"NA","overall_status":"RECRUITING","enrollment_count":9000,"lead_sponsor_name":"Noguchi Memorial Institute for Medical Research","has_results":false},{"nct_id":"NCT04093765","title":"Mass Screening and Treatment for Reduction of Falciparum Malaria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5542,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03923725","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2583,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT00322738","title":"Time to Infection With Malaria Parasites","phase":"","overall_status":"COMPLETED","enrollment_count":2558,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00322816","title":"Malaria Prevalence in Children","phase":"","overall_status":"COMPLETED","enrollment_count":2552,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04473768","title":"Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children","phase":"","overall_status":"COMPLETED","enrollment_count":1880,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT05842954","title":"Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05951595","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1680,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06076213","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1260,"lead_sponsor_name":"Ministry of Public Health, Democratic Republic of the Congo","has_results":false},{"nct_id":"NCT05400655","title":"Anti-malaria MAb in Kenyan Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":912,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05058885","title":"Plasmodium Vivax Among Duffy Negative Population in Cameroon.","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"University of Dschang","has_results":false},{"nct_id":"NCT03172221","title":"Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women","phase":"","overall_status":"COMPLETED","enrollment_count":880,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT03996967","title":"Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia","phase":"","overall_status":"COMPLETED","enrollment_count":837,"lead_sponsor_name":"Boston University","has_results":false},{"nct_id":"NCT02001428","title":"Malaria in Early Life Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":757,"lead_sponsor_name":"Gadjah Mada University","has_results":false},{"nct_id":"NCT05567016","title":"CHILD (Child Health and Infection With Low Density) Malaria","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT01736319","title":"Artemisinin-resistant Malaria in Cambodia","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03167242","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":524,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03916003","title":"Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT00314899","title":"Fetal Immunity to Falciparum Malaria","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05816330","title":"L9LS MAb in Malian Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04422015","title":"Biological Mechanisms in Afebrile P. Falciparum Malaria","phase":"","overall_status":"COMPLETED","enrollment_count":475,"lead_sponsor_name":"Alfredo Mayor","has_results":false},{"nct_id":"NCT03764527","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Professor Anders Björkman","has_results":false},{"nct_id":"NCT05764746","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":384,"lead_sponsor_name":"Muhimbili University of Health and Allied Sciences","has_results":false},{"nct_id":"NCT07194668","title":"R21/MM Dosing, Presentations, and Preservatives","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":375,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05304611","title":"Anti-malaria MAb in Malian Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":365,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT03768908","title":"Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":359,"lead_sponsor_name":"Professor Anders Björkman","has_results":false},{"nct_id":"NCT06300970","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT04329104","title":"Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04147546","title":"Additional Screening With Sensitives RDTs and Malaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Institut de Recherche en Sciences de la Sante, Burkina Faso","has_results":false},{"nct_id":"NCT03431714","title":"Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"National Institute for Medical Research, Tanzania","has_results":false},{"nct_id":"NCT05750628","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":327,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03453840","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04546633","title":"Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03726593","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Armed Forces Research Institute of Medical Sciences, Thailand","has_results":false},{"nct_id":"NCT02612545","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04829695","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":184,"lead_sponsor_name":"University of Yaounde 1","has_results":false},{"nct_id":"NCT05192265","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"University of Ibadan","has_results":false},{"nct_id":"NCT04222088","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","phase":"","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Research Institute for Tropical Medicine, Philippines","has_results":true},{"nct_id":"NCT02645604","title":"Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03773536","title":"Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Professor Anders Björkman","has_results":false},{"nct_id":"NCT03939104","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05958693","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2015","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Research Institute for Tropical Medicine, Philippines","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}